Finally, given that combined inhibition of BRAF/MEK is associated with improved clinical outcomes among patients with BRAF V600-mutated metastatic melanoma [10], we further assessed whether the addition of IL-18 to IL-15 was also able to rescue NK suppression induced by BRAF/MEK co-inhibition. The gene discussed is MAP2K7; the disease is metastatic melanoma.